The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|September 19, 2018
Rheumatoid Arthritis Comorbidities: A 5-Question Quiz
Test your knowledge of RA comorbidities with this short quiz.
Advertisement
This month’s quiz focuses on comorbidities you may encounter in your patients with rheumatoid arthritis (RA). Ready to test your knowledge? Let’s get started.
Question 1.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement